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Recent studies have found that hundreds of genetic variants, including common and rare
variants, rare and de novo mutations, and common polymorphisms contribute to the
occurrence of autism spectrum disorders (ASDs). The mutations in a number of genes
such as neurexin, neuroligin, postsynaptic density protein 95, SH3, and multiple ankyrin
repeat domains 3 (SHANK3), synapsin, gephyrin, cadherin, and protocadherin, thousand-
and-one-amino acid 2 kinase, and contactin, have been shown to play important roles
in the development and function of synapses. In addition, synaptic receptors, such as
gamma-aminobutyric acid receptors and glutamate receptors, have also been associated
withASDs.This review will primarily focus on the defects of synaptic proteins and receptors
associated with ASDs and their roles in the pathogenesis of ASDs via synaptic pathways.
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INTRODUCTION
Autism spectrum disorders (ASDs) are a heterogeneous group of
neurodevelopmental disorders characterized by social communi-
cation deﬁcits and stereotyped behaviors with restricted interests
(American Psychiatry Association [APA], 2013). Autism was ﬁrst
reported by Kanner (1943), who described seven boys and four
girls who exhibited “extreme aloneness from the very beginning
of life, not responding to anything that comes to them from the
outside world.” Asperger (1944) described four boys with social
communication difﬁculties. During the past 70 years, the deﬁ-
nition of autism has developed as understanding of the disorder
increased. It was ﬁrst introduced as infantile autism in the ofﬁcial
diagnostic nomenclature in the third edition of theDiagnostic and
Statistical Manual of Mental Disorders (DSM-III), was referred to
as Pervasive Developmental Disorders (PDD) in DSM-IV and was
deﬁned as ASDs in the latest revision of the DSM, DSM-V (Amer-
ican Psychiatry Association [APA], 2013), which was published
in May 2013. In DSM-V, ASDs includes disorders that were pre-
viously diagnosed separately, such as autistic disorder, Asperger’s
disorder, childhooddisintegrative disorder, andpervasive develop-
mental disorder not otherwise speciﬁed. The decision tomerge the
three disorders was taken because they could not be easily distin-
guished from each other. Studies have shown that more than half
of adults with autism have poor or very poor outcomes (Howlin
et al., 2004; Billstedt et al., 2005) in terms of independent living,
educational attainment, employment, and peer relationships.
Autism was considered as a rare childhood disorder, and in the
ﬁrst epidemiological study conducted in the UK in 1966, Lotter
(1966) reported a prevalence rate of autism of 4.5 in 10,000 chil-
dren. However, the prevalence of ASDs has steadily increased in
the past two decades; for example, in the USA the estimated preva-
lence was reported to be 19 in 10,000 children in 1992 increasing to
1 in 150 in 2002, 1 in 110 in 2006, and 1 in 88 in 2008 (Rice, 2012).
ASDs are recognized as a common disorder today, with a median
worldwide prevalence of 0.62% (Elsabbagh et al., 2012), and boys
are affected by ASDs four times more frequently than girls. The
increased prevalence of ASDs is most likely because of broadened
diagnostic criteria and heightened awareness, but may also par-
tially reﬂect a true increase due to environmental factors acting
upon a genetically vulnerable background (King and Bearman,
2009; Lintas and Persico, 2009; Li et al., 2012).
In addition to a variable severity of the core deﬁcits, ASDs
patients also present other psychiatric and medical conditions,
such as intellectual disability, epilepsy, motor control problems,
attention-deﬁcit/hyperactivity disorder, tics, anxiety, sleep disor-
ders, and gastrointestinal problems (Simonoff et al., 2008; Lai et al.,
2014).
For the past several decades, ASDs have been recognized as a
complex brain disorder with high heritability, except with rare
pedigrees, usually accompanied with other neurodevelopmental
conditions shown to have Mendelian inheritance (Morrow et al.,
2008; Novarino et al., 2012). Recent genomic and genetic studies
have found that hundreds of genetic variants, including common
and rare variants, contribute to the occurrence of ASDs. Rare and
de novo mutations may pose a substantial risk for ASDs and play a
substantial role in population risk, and common polymorphisms
also contribute to ASDs. The role of individual alleles remains elu-
sive and underestimated due to their small effect sizes (Murdoch
and State, 2013). Many genes associated with ASDs play roles in
the development and function of synapses, such as neuroligin 3
(NLGN3), NLGN4X, neurexin 1 (NRXN1), and SH3, and multiple
ankyrin repeat domains 3 (SHANK3).
Post-mortem studies of ASDs patients have shown a reduc-
tion in the number of neurons in the amygdala, fusiform gyrus,
Frontiers in Cellular Neuroscience www.frontiersin.org September 2014 | Volume 8 | Article 276 | 1
Chen et al. Synaptic defects in ASDs
and cerebellum and signs of persistent neuroinﬂammation (Lai
et al., 2014). In addition, reduction in the density of serotonin
transporters (5-HTT) was also found in the deep layers of the
fusiform gyrus in autistic subjects (Oblak et al., 2013). Transcrip-
tome analyses showed that genes involved in synaptic function
were downregulated in the ASDs post-mortem brain. Moreover,
the emergence of various types of genetically modiﬁed mouse
models targeting ASDs-associated genes or loci in recent years
have provided insights into particular aspects of ASDs. Therefore,
it may be proposed that ASDs are a synaptic defect disease. In
this review, we will focus on the role of synaptic-related genes in
ASDs.
SYNAPTIC PROTEINS, RECEPTORS, AND AUTISM
SPECTRUM DISORDERS
SYNAPTIC PROTEINS AND AUTISM SPECTRUM DISORDERS
Neurexin (NRXN)
Neurexins (NRXN) are a family of synaptic adhesion pro-
teins that are located on the presynaptic membrane and bind
to their postsynaptic counterpart, NLGNs. The NRXN fam-
ily consists of three genes (NRXN1, NRXN2, and NRXN3),
each of them generating a long mRNA encoding α-NRXN
and a short mRNA encoding β-NRXN from two indepen-
dent promoters. The intracellular domains of α-NRXNs and
β-NRXNs are identical, whereas the extracellular domains are
different. Speciﬁcally, the extracellular domains of α-NRXNs
contain six laminin, nectin, and sex-hormone binding globu-
lin (LNS) domains and three epidermal growth factor (EGF)
domains, which form three repeated LNS (A)-EGF-LNS (B) struc-
ture. However, β-NRXNs have no EGF domain and only one
LNS domain (Tabuchi and Sudhof, 2002). NRXN1, NRXN2,
and NRXN3 are located on chromosomes 2p16.3, 11q13, and
14q31, respectively. α-NRXN triple knockout mice had reduced
synaptic Ca2+ channel function, which causes impaired spon-
taneous and evoked neurotransmitter release (Missler et al.,
2003).
Rare copy number variations and/or point mutations in NRXN
genes have been repeatedly reported to be associated with ASDs
(Table 1). Friedman and Luiselli (2008) ﬁrst reported a 320 kb
de novo heterozygous deletion of the NRXN-1α promoter and
exons 1–5 in a boy with cognitive impairment, autistic fea-
tures and physical dysmorphism. Later, the Autism Genome
Project Consortium et al. (2007) identiﬁed a de novo heterozy-
gous deletion that eliminated several NRXN1 exons, including
1α and 1β, in two affected female siblings in one ASDs fam-
ily. Several other studies have also reported deletions in NRXN1
in ASDs patients (Kim et al., 2008; Marshall et al., 2008; Mor-
row et al., 2008; Glessner et al., 2009; Pinto et al., 2010; Bremer
et al., 2011; Levy et al., 2011). To date, no homozygous dele-
tions in NRXN1 have been found, which may suggest that the
dosage of NRXN1 is very important for neurological develop-
ment. P300P, an NRXN1 common variant, was associated with
ASDs in a Chinese ASDs patient. In addition to being associated
with ASDs, NRXN1 deletions have also been reported in other
psychiatric conditions, such as schizophrenia, bipolar disorder,
attention deﬁcit hyperactivity disorder, and Tourette syndrome
(International SchizophreniaConsortium,2008;Walsh et al., 2008;
Guilmatre et al., 2009; Zhang et al., 2009; Sundaram et al., 2010;
Lionel et al., 2011).
A truncated mutation of NRXN2 inherited from a father with
severe language delay and a family history of schizophrenia was
identiﬁed by Gauthier et al in an ASDs patient (Gauthier et al.,
2011). NRXN3 deletions have also been found in four ASD indi-
viduals: one was a de novo mutation, two were inherited from a
non-affectedmother or father, and onewas inherited from a father
with subclinical autism (Vaags et al., 2012).
NRXN animal models have provided evidence supporting the
role of NRXN in ASDs pathology. NRXN1α KO mice showed a
defect in excitatory synaptic strength, with a decrease in miniature
excitatory postsynaptic current frequency and in the input–output
relation of evoked postsynaptic potentials (Etherton et al., 2009).
Behavioral studies have shown thatNRXN-1 deﬁcientmice display
decreased prepulse inhibition and increased grooming behaviors
but no obvious changes in social behaviors or spatial learning
(Etherton et al., 2009). Studies in an α-NRXN triple KO mice
with all three α-NRXNs (Nrxn1α/2α/3α) deleted have shown that
α-NRXNswere not required for synapse formationbutwere essen-
tial for Ca2+-triggered neurotransmitter release (Missler et al.,
2003).
Contactin associated protein-2 (CNTNAP2, also known as
Caspr2) is a member of the NRXN superfamily and is involved in
neuron–glia interactions and clusteringK+ channels inmyelinated
axons. Strauss et al. (2006) identiﬁed a homozygous mutation
of CNTNAP2 in Amish children with PDD, seizures, and lan-
guage regression (Strauss et al., 2006; Table 1). Bakkaloglu et al.
(2008) found 13 rare non-synonymous variants unique to ASDs
patients, which suggests that ASDs patients carry more CNTNAP2
rare variants. Several other studies have also found other com-
mon polymorphisms of CNTNAP2 that are associated with ASDs
(Alarcón et al., 2008; Arking et al., 2008; Sampath et al., 2013).
Interestingly, Alarcón et al. (2008) found that CNTNAP2 provided
a strong male affection bias in ASDs.
CNTNAP2 KO mice exhibited deﬁcits in the core ASDs behav-
ioral domains, such as stereotypic motor movements, behavioral
inﬂexibility, communication, and social behavior abnormalities
(Peñagarikano et al., 2011).
Neuroligin (NLGN)
Neuroligins (NLGN) are a different type of synaptic cell adhesion
proteins that are located in the postsynaptic membrane. NLGNs
bind to their adhesive counterpart NRXNs and play an impor-
tant role in synapse formation and function (Figure 1). The
human NLGN family includes ﬁve NLGN genes (NLGN1, 2, 3,
4, 4Y), which are localized at 3q26 (NLGN1), 17p13 (NLGN2),
Xq13 (NLGN3), Xp22.3 (NLGN4), and Yq11.2 (NLGN4Y ).
NLGNs contain a large extracellular domain that shares sequence
homology with acetylcholinesterase and that is necessary for
β-NRXN binding and synaptogenic activity, two EF-hand motifs
that bind to Ca2+, an O-glycosylation region, a transmem-
brane domain, and a cytoplasmic C-terminal tail that contains
a PSD-95/Dlg/ZO-1 (PDZ) interaction site (Dean and Dres-
bach, 2006; Figure 1). NLGNs-1, -3, and -4 localize mainly
to glutamate synaptic sites, whereas NLGN-2 localizes primar-
ily to gamma-aminobutyric acid (GABA) synapses (Missler et al.,
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Table 1 | Summary of different defects in gene encoding for synaptic proteins in autism spectrum disorders.
Synaptic gene Loci Type of genetic defects Reference
NRXN1 2p16.3 de novo heterozygous deletion Autism Genome Project Consortium et al. (2007)
Deletion Pinto et al. (2010), Bremer et al. (2011)
NRXN2 11q13 Truncated mutation Gauthier et al. (2011)
NRXN3 14q31 de novo deletion Vaags et al. (2012)
Inherited deletion Vaags et al. (2012)
CNTNAP2 Homozygous mutation Strauss et al. (2006)
Rare non-synonymous variants Bakkaloglu et al. (2008)
Common polymorphisms Alarcón et al. (2008), Sampath et al. (2013)
NLGN1 3q26 Common variants (rs1488545) Talebizadeh et al. (2004), Gauthier et al. (2005)
NLGN3 Xq13 R451C transition Jamain et al. (2003), Földy et al. (2013)
Common variants (DXS7132) Talebizadeh et al. (2004)
NLGN4 Xp22.3 Frameshift mutation (1186insT) Laumonnier et al. (2004)
Missense mutation Yan et al. (2005)
Deletion (1253delAG) Laumonnier et al. (2004)
Common variants (DXS996) Talebizadeh et al. (2004)
SHANK3 22q13.3 Deletion Durand et al. (2007), Gauthier et al. (2009)
Novel non-synonymous variants Moessner et al. (2007)
Missense mutation Gauthier et al. (2009)
de novo heterozygous insertion Durand et al. (2007)
SHANK2 de novo nonsense mutation Berkel et al. (2010), Pinto et al. (2010)
SHANK1 Inherited deletion Sato et al. (2012), Guilmatre et al. (2013)
PSD-95 Deletion Feyder et al. (2010)
Synapsin1 Xp11.23 Nonsense mutation (Q555X ) Fassio et al. (2011)
Mutations (A51G, A550T, T567A) Fassio et al. (2011)
Synapsin2 3p25.2 Nonsense mutation (p.A94fs199X) Corradi et al. (2014)
Missense mutation (p.Y236S, p.G464R) Corradi et al. (2014)
Gephyrin Hemizygous deletions Lionel et al. (2013)
de novo deletion Lionel et al. (2013)
Paternally inherited deletion Lionel et al. (2013)
CDH13 16q23 Recurrent larger genomic deletions Sanders et al. (2011)
PCDHA SNP Anitha et al. (2013)
PCDH9 CNV Betancur et al. (2009)
PCDH10 Homozygous deletion Betancur et al. (2009)
TAOK2 16p11.2 Novel, recurrent microdeletion Weiss et al. (2008)
de novo deletion Weiss et al. (2008)
Reciprocal microduplication Weiss et al. (2008)
CNTN4 Disruption Roohi et al. (2009), Guo et al. (2012)
NRXN: neurexin; CNTNAP2: contactin associated protein-2; NLGN: neuroligin; CDH: cadherin; PCDH: protocadherin; TAOK2: thousand-and-one-amino acid 2 kinase;
CNTN: contactin; CNV: copy number variation; SNP: Single-nucleotide polymorphism.
2003; Figure 1). In vitro and in vivo, NLGN-1 overexpression
increases excitatory synaptic responses and potentiates synaptic
NMDA receptor (NMDAR)/AMPAR ratios. In contrast, NLGN-2
overexpression increases inhibitory synaptic responses. Accord-
ingly, the inhibition of NLGN-1 expression selectively decreases
the NMDAR/AMPAR ratio, whereas the deletion of NLGN-2
selectively decreases inhibitory synaptic responses. Furthermore,
NLGN-1 expression selectively increases the maturation but not
initiation of excitatory synapse formation in adult-born neurons
(Chubykin et al., 2007; Schnell et al., 2012).
The earliest report regarding the potential association of NLGN
genes and ASDs is Jamain et al. (2003; Table 1). In one ASDs
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FIGURE 1 |The main synaptic proteins and receptors involved in this
review in synaptogenesis and function. (1) Neuroligins(NLGNs) can
bind to neurexins (NRXNs), Ca2+ channel and shank through their
different domains to play an important role in synapse maturation and
function. NLGNs 1, 3, and 4 localize to excitatory synaptic sites, whereas
NLGN -2 localizes primarily to inhibitory synapses. Shank are synaptic
scaffold proteins that bind NLGN–NRXN and NMDA receptor complexes
at the postsynaptic density of excitatory glutamatergic synapses. Multiple
domains of shank are useful for protein–protein interaction, such as
linking to actin cytoskeleton, binding to glutamate receptor-interacting
protein to link with α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid
receptors. Postsynaptic density protein 95 (PSD-95) serves as a major
functional bridge interconnecting the NRXN -NLGN -SHANK pathway. (2)
Gephyrin is a key scaffold molecule of the postsynaptic membrane at
inhibitory synapses. Gephyrin can interact with glycine receptor and alpha
and beta subunits of the gamma-aminobutyric acid A (GABAA) receptor to
mediate inhibition of synapse formation and function. NLGN 2 can bind
to protein gephyrin and activate collybistin. NLGN 2, gephyrin, and
collybistin complexes are sufﬁcient to inhibitory neurotransmitter receptors
clustering.
multiplex family, the group found three ASDs siblings carrying
one frameshift mutation (1186insT) of NLGN4 that was inher-
ited from the non-affected mother, creating a stop codon that
led to a premature termination of the protein. In another family,
a R451C transition in NLGN3 that changed a highly conserved
arginine residue into cysteine within the esterase domain was
identiﬁed in two affected siblings. This point mutation was inher-
ited from the non-affected mother. A study in a large French
family found a 2 bp deletion (1253delAG) that resulted in a
premature stop codon in the middle of the sequence of the
normal NLGN4 gene (Laumonnier et al., 2004). In this fam-
ily, 10 males had non-speciﬁc X-linked mental retardation, two
had autism, and one had pervasive developmental disorder. All
affected patients had the same frameshift mutation. Missense
changes in NLGN4 were also found in Portuguese ASDs fami-
lies (Yan et al., 2005). A study in a small Finnish autism sample did
not ﬁnd any functional mutation of NLGN1, NLGN3, NLGN4,
or NLNG4Y, although three common variants (rs1488545 in
NLGN1, DXS7132 in NLGN3, and DXS996 in NLGN4) that
showed minor association with ASDs were found. Despite the
evidence that NLGN is associated with ASDs, several studies have
failed to ﬁnd associations between rare mutations and common
variants and ASDs (Talebizadeh et al., 2004; Vincent et al., 2004;
Gauthier et al., 2005; Blasi et al., 2006; Wermter et al., 2008; Liu
et al., 2013).
Several NLGN mutant mouse models have been developed
to investigate the role of NLGN mutations in ASDs. Nlgn3
R451C knock-in mice, which corresponded to the human non-
synonymous SNP (R451C) in NLGN3 found in ASDs patients
(Jamain et al., 2003), showed social interaction deﬁcits and
increased spatial memory and an electrophysiological pheno-
type consisting of increased inhibitory synaptic transmission in
the somatosensory cortex (Tabuchi et al., 2007; Etherton et al.,
2011a). Furthermore, researchers found that both NLGN-3
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R451C-knockin andNLGN-3 knockoutmutations inmice showed
impairment in tonic endocannabinoid signaling (Földy et al.,
2013). Another NLGN3 mutation, R704C, was introduced into
mouse NLGN-3 by homologous recombination, and electrophys-
iological and morphological studies have shown that although
the NLGN-3 R704C mutation did not signiﬁcantly alter synapse
formation, it dramatically impaired synapse function. More-
over, the R704C mutation caused a major and selective decrease
in AMPA receptor-mediated synaptic transmission in pyramidal
neurons of the hippocampus, without similarly changing NMDA
or GABA receptor-mediated synaptic transmission and without
detectably altering presynaptic neurotransmitter release (Etherton
et al., 2011b). Mice lacking the human NLGN4 (NLGN4-KOs)
ortholog exhibited highly selective deﬁcits in reciprocal social
interactions and communication reminiscent of ASDs (Jamain
et al., 2008).
Shank
Shank family proteins, also known as ProSAP, are synaptic scaf-
fold proteins that bind NLGN-NRXN and NMDAR complexes
at the postsynaptic density (PSD) of excitatory glutamatergic
synapses (Figure 1). There are three genes that encode Shank pro-
teins (SHANK1, SHANK2, and SHANK3). All Shank proteins are
expressed in the brain but exhibit different patterns. Shank1 is
expressed in most parts of the brain, except for the striatum, and
it is highly expressed in the cortex and hippocampus. Shank2 and
Shank3 are also present in the cortex and hippocampus. Shank2
is mostly absent from the thalamus and striatum, whereas Shank3
appears to be predominantly expressed in those regions. In the
cerebellum, Shank2 is restricted to Purkinje cells, whereas Shank3
is restricted to granule cells (Sheng and Kim, 2000). SHANK
directly or indirectly binds to NLGNs in the PSD. In vitro and
in vivo studies highlight the important role of Shank3 for synap-
tic function. SHANK3 functions as a scaffolding protein in spine
morphogenesis and synaptic plasticity. Knockdown of Shank3 in
cultured hippocampal neurons leads to a reduced number and
increased length of dendritic spines. When overexpressed in cul-
tured hippocampal neurons, Shank3 promotes thematuration and
enlargement of dendritic spines (Betancur et al., 2009). Knock-
down of Shank3 in hippocampal neurons decreases spiny density,
whereas transfection of Shank3 in aspiny neurons induces the for-
mation of dendritic spines with functional synapses (Betancur
et al., 2009).
Shank contains multiple domains for protein–protein inter-
action, including ankyrin repeats (binding to α-fodrin to link
to the actin cytoskeleton and calpain/calmodulin-mediated Ca2+
signaling), an SH3 domain (binding to glutamate receptor-
interacting protein to link with α-amino-3-hydroxy-5-methyl-
4-isoxazolepropionic acid (AMPA) receptors to the postsynaptic
scaffold), a PDZ domain (binding different molecules within the
PSD, including GKAP, to allow Shank to attach to PSD-95), a
proline-rich region (which contains sites for Homer and cor-
tactin), and a sterile alpha motif domain (which is involved in
the polymerization of Shank molecules; Lim et al., 1999; Yoo et al.,
2014; Figure 1).
SHANK3 was the ﬁrst gene in the SHANK family reported
to be associated with ASDs (Table 1). The SHANK3 gene is
located on chromosome 22q13.3 within the critical region of
22q13.3 deletion syndrome (also known as Phelan-McDermid
syndrome, PMS). 22q13.3 deletion syndrome is characterized
by neonatal hypotonia, global developmental delay, absent or
severely delayed speech, autistic behaviors, and intellectual disabil-
ity (Phelan, 2008). The size of the deleted segments varied widely
in individuals with this syndrome, but deletions of SHANK3 were
present in nearly all cases (Wilson et al., 2003, 2008; Dhar et al.,
2010). Three ASDs families were observed to carry alterations of
22q and/or the SHANK3 gene (Durand et al., 2007). In one fam-
ily, an individual carried a de novo deletion of 22q13, in which
the deletion breakpoint was located in intron 8 of SHANK3 and
a 142 kb of the terminal 22q13 was removed. In the second fam-
ily, two affected siblings were heterozygous for an insertion of
a guanine nucleotide in exon 21, and the mutation was a de
novo mutation. In the third family, a terminal 22q deletion was
identiﬁed in a girl with autism who exhibited severe language
delay. A 22qter partial trisomy in her brother who had Asperger
syndrome was also identiﬁed, although the boy demonstrated
precocious language development and ﬂuent speech. These unbal-
anced cytogenetic abnormalities were inherited from a paternal
translocation, t(14;22) (p11.2;q13.33). This ﬁnding suggests a gene
dosage effect of SHANK3. A study of SHANK3 variants by screen-
ing SHANK ’s exon sequence in 400 ASDs families found 10 novel
non-synonymous variants inASDs (Moessner et al., 2007). Among
these mutations, one was a de novo mutation, and the other nine
were all inherited from one unaffected parent. Rare functional
mutations of SHANK3 have been identiﬁed in two ASDs families.
One was a de novo deletion at an intronic donor splice site, and
one was a missense mutation inherited from an epileptic father
(Gauthier et al., 2009). Moreover, three deleterious variants (one
6-amino acid deletion upstream of the SH3 domain, one mis-
sense variant in the PDZ domain, and one insertion/deletion of
a repeated 10 bp GC sequence located 9-bp downstream from
the 3′ end of exon 11) were found in Japanese ASDs families
(Waga et al., 2011). It has been reported that 2.3% of ASDs
patients carry deleterious mutations in SHANK3 (Boccuto et al.,
2013).
Several studies have identiﬁed de novo deleterious mutations of
SHANK2 in ASDs (Berkel et al., 2010; Pinto et al., 2010; Leblond
et al., 2012; Table 1). In one study, a de novo nonsense muta-
tion, seven rare inherited changes and additional variants speciﬁc
to ASDs were identiﬁed by sequencing SHANK2 in 396 ASDs
patients. In a separate study, SHANK2 was sequenced in 455
patients. When combining the results of these two studies, a sig-
niﬁcant enrichment of variants affecting conserved amino acids
in 29 of 851 (3.4%) patients and 16 of 1090 (1.5%) controls
was observed. In neuronal cell cultures, the variants identiﬁed in
patients were associatedwith reduced synaptic density at dendrites
compared with the variants only detected in controls (Leblond
et al., 2012).
The SHANK1 gene rare mutation has also been associated with
ASDs (Sato et al., 2012; Table 1). An inherited deletion of 63.8 kb
encompassing SHANK1 and the CLEC11A gene was found in a
multigenerational family. In this family, four males carrying this
deletion showedhigh-functioning autismor a broader autismphe-
notype, whereas the two females carrying the same deletion were
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not affected by ASDs (Sato et al., 2012). SHANK1 deletions may
be associated with high-functioning autism in males (Guilmatre
et al., 2013).
Genetic mouse models resembling different SHANK muta-
tions have been created to investigate the role of Shank in synapse
conformation and function and its contribution to autistic pathol-
ogy. Shank1 mutant mice (with a deletion of exons 14 and 15,
which includes most of the PDZ region, resulted in the knock-
out of all detectable Shank1 protein in these animals) showed
decreased movement in the open ﬁeld and deﬁcits in motor
learning and contextual fear conditioning. Although these ani-
mals did not show apparent repetitive behaviors and seemed to
have normal levels of social interaction, they showed a general
deﬁcit in social communicative behaviors by bothultrasonic vocal-
izations and urine-based communicative behaviors (Hung et al.,
2008; Silverman et al., 2011; Wöhr et al., 2011). Shank2 mutant
mice, mimicking the human microdeletion of exons 6 and 7,
which targeted the PDZ domain and knocked out of all Shank2
isoforms, also showed alterations in behavior and synaptic plas-
ticity (Schmeisser et al., 2012; Won et al., 2012). Shank3 exons
4–9 KO mice (resulting in the loss of the longest two isoforms
of Shank3) were used to mimic human SHANK3 mutation by
several research groups. Although the deﬁcits in social interac-
tion in these models were not consistent (Bozdagi et al., 2010;
Peça et al., 2011; Yang et al., 2012), all of the models showed a
repetitive self-grooming phenotype (Wang et al., 2011; Yang et al.,
2012).
PSD-95
Postsynaptic density protein 95 (PSD-95; also known as DLG4,
SAP90), is a member of the membrane-associated guanylate
kinase family of synaptic molecules and serves as a major
functional bridge interconnecting the NRXN-NLGN-SHANK
pathway (Figure 1). PSD-95 contains three PDZ domains, a
single interior SH3 domain, and a COOH-terminal guanylate
kinase domain. The cytoplasmic domains of all three NLGNs
bind to the third PDZ domain of PSD-95, whereas NMDA2
receptors and K+channels bind to the ﬁrst and second PDZ
domains. PSD-95 is localized at excitatory synapses and has
been implicated in promoting synapse stability. PSD-95 makes
synaptic contacts more stable in older neurons than in younger
neurons.
PSD-95 knockout mice exhibit reduced AMPAR function
and a decreased frequency of AMPAR-mediated miniature
EPSCs, suggesting that PSD-95 may regulate synaptic mat-
uration through postsynaptic AMPA-type glutamate receptors
(GluARs).
Thus far, no rare point mutation or CNV or common vari-
ants have been reported to be associated with ASDs, but PSD-95
deletion (Dlg4−/−) mice have been shown to exhibit a com-
plex range of behavioral and molecular abnormalities relevant to
ASDs (Table 1). Dlg4−/− mice showed increased repetitive behav-
iors, abnormal communication and social behaviors, impaired
motor coordination, increased stress reactivity, and anxiety-
related responses. Dlg4−/− mice also had subtle dysmorphology
of amygdala dendritic spines and altered forebrain expression of
various synaptic genes (Feyder et al., 2010).
Synapsin
The synapsins are a family of presynaptic phosphoproteins that
account for 9% of the vesicle protein and can regulateneuro-
transmitter release and neurite outgrowth (Rosahl et al., 1995).
Synapsins contain a mosaic of conserved (A–C, E) and indi-
vidual domains (D, F–J). They have three family members in
mammals (synapsin 1, synapsin 2, and synapsin 3), which
locate on chromosomes Xp11.23, 3p25.2, and 22q12.3, respec-
tively. Cultured neurons from synapsin 1,2,3(–/–) triple knock-out
mice exhibit severely dispersed synaptic vesicles and considerably
reduced synaptic vesicles number (Fornasiero et al., 2012).
Mutations in synapsin 1 (Q555X, A51G, A550T, and T567A)
were found in a large French-Canadian family with epilepsy
and ASDs (Fassio et al., 2011; Table 1). Furthermore, the non-
sense Q555X mutation can reduce the phosphorylation caused by
CaMKII and Mapk/Erk, which regulate synaptic vesicles trafﬁck-
ing and neurite outgrowth. The missense mutation of A550T and
T567A can impair the targeting to nerve terminals (Fassio et al.,
2011).
Synapsin 2 has also been identiﬁed as an autism predisposing
gene. In a study involving 190 individuals with ASDs, researchers
found one nonsense mutation (p.A94fs199X) and two missense
mutations of synapsin 2 (p.Y236S and p.G464R; Corradi et al.,
2014; Table 1).
Synapsin knockout mice may be identiﬁed as a useful exper-
imental model of ASDs and epilepsy. Researchers found that
synapsin knockout mice exhibit social novelty abnormality and
avoidance behavior in social approach which are reminiscent
of ASDs. Speciﬁcally, synapsin 2 deletion mice display deﬁcits
in short-term social recognition and increased repetitive self-
grooming behavior. Synapsin 1and synapsin 3 deletion mice dis-
play an impaired social transmission of food preference. Synapsin
1and synapsin 2 deletion mice display a decreased environmental
interest (Greco et al., 2013). The results demonstrate an involve-
ment of synapsins in the development of the behavioral traits of
ASDs.
Gephyrin
Gephyrin is a key scaffold molecule of the postsynaptic membrane
at inhibitory synapses (Figure 1). It contains three domains, G
domain in N-terminal, E-domain in C-terminal, and a large linker
domain of the two. Gephyrin can interact with glycine receptor
and alpha and beta subunits of the GABAA receptor to medi-
ate inhibition. NLGN 2 can bind to protein gephyrin through a
conserved cytoplasmic motif and activate collybistin. NLGN 2,
gephyrin, and collybistin complexes are sufﬁcient to inhibitory
neurotransmitter receptors clustering. Deletion of NLGN 2 in
mice leads to a loss of recruitment of gephyrin at perisomatic but
not dendritic sites (Poulopoulos et al., 2009; Table 1). Gephyrin-
deﬁcientmice die early postnatally and display loss of postsynaptic
GABA(A) receptor and glycine receptors clustering, whereas glu-
tamate receptor subunits were normally localized (Kneussel et al.,
1999; Grosskreutz et al., 2003).
Exonic microdeletions in gephyrin gene have been reported a
correlation with neurodevelopmental disorders including ASDs
(Lionel et al., 2013). In one family, the proband with ASDs
has a 357 kb de novo deletion in gephyrin and exhibits limited
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movement, slowmotor development, and language delay. The sec-
ond family has a 319 kb paternally inherited deletion in gephyrin
and exhibits mild global developmental delay in early life, social
difﬁculties, and repetitive behaviors. The third family has a 273 kb
de novo deletion in gephyrin gene and exhibits developmental
delay, cyclical seizures, and behavioral issues including anxiety,
obsessive compulsive disorders, tics, and impulsive behaviors
(Lionel et al., 2013).
Cadherins (CDHs) and protocadherins (PCDHs)
Cadherins (CDHs) are a family of glycosylated transmembrane
proteins that mediate cell–cell adhesion, neuronal migration,
spine morphology, synapse formation, and synaptic remod-
eling (Redies et al., 2012). Because the function of CDHs is
dependent on the presence of Ca2+, they are named for the
Ca2+-dependent cell adhesion molecule family. The CDH fam-
ily is classiﬁed into classical CDHs, desmosomal cadherins, and
protocadherins (PCDHs). Genome-wide association studies on
a cohort of 4305 autistic subjects have shown that common
variants between the CDH9 and CDH10 genes on chromosome
5p14.1 are associated with autism (Wang et al., 2009). Similarly,
recurrent larger genomic deletions in 16q23 in CDH13 was also
observed in ASDs patients in 1124 ASDs families participating
in genome-wide analyses (Sanders et al., 2011; Table 1). Fur-
thermore, after the detection of 14 SNPs of protocadherin α
in DNA samples of 3211 individuals with autism, 5 SNPs were
showed signiﬁcantly associated with autism (Anitha et al., 2013).
In addition, CNVs in PCDH9 and homozygous deletions in
PCDH10 have also been reported in ASDs (Betancur et al., 2009;
Table 1).
In situ hybridization analysis in the embryonic and postnatal
mouse demonstrated that CDH8 expression is restricted to spe-
ciﬁc developing gray matter structures. Later, a study using the
PPL statistical framework identiﬁed that CDH8 is expressed in the
developing human cortex of ASDs family, which implicates CDH8
in susceptibility to autism (Redies et al., 2012).
Thousand-and-one-amino acid 2 kinase (TAOK2)
Thousand-and-one-amino acid 2 kinase (TAOK2), also known as
TAO2, is a serine/threonine-protein kinase that is encoded by the
TAOK2 gene in humans. It can activate mitogen-activated protein
kinase (MAPK) pathways to regulate gene transcription. TAOK2
interact with semaphorin 3A receptor neuropilin 1, which reg-
ulates basal dendrite arborization. In addition, TAOK2 can be
phosphorylated and activated by Sema3A. In cultured cortical
neurons, TAOK2 downregulation can decrease JNK phosphory-
lation and cause its inactivation. Furthermore, basal dendrite
formation in cortical neurons caused by TAOK2 downregula-
tion can be rescued by active JNK1 overexpression. TAOK2 is
involved in membrane blebbing, the DNA damage response, and
theMAPK14/p38MAPKstress-activatedMAPKcascade. Recently,
TAOK2 has been shown to play a role in basal dendrite formation
(de Anda et al., 2012).
TheTAOK2 gene is located in the 16p11.2 chromosomal region.
Approximately 1% of autistic subjects have been shown to have
a novel, recurrent microdeletion, a de novo deletion of 593 kb
on chromosome 16p11.2, and a reciprocal microduplication on
chromosome 16p11.2 (Weiss et al., 2008), suggesting that 16p11.2
or the TAOK2 gene is involved in susceptibility to ASDs (Table 1).
Contactin (CNTN)
Contactins (CNTNs) are members of the immunoglobulin super-
family. They are glycosylphosphatidylinositol-anchored neuronal
membrane proteins and play important roles in axon growth and
guidance and synapse formation and plasticity.
Array-based comparative genomic hybridization identiﬁed a
paternally inherited chromosome 3 copy number variation in
three autistic subjects. Speciﬁcally, a deletion in two siblings and
a duplication in an unrelated individual were detected. Further-
more, these variations were mediated by disruptions of CNTN4
(Roohi et al., 2009), suggesting that CNTN4 may be involved in
ASDs (Table 1). Recently, a study conducted in a Chinese popula-
tion also came to the same conclusion (Guo et al., 2012). Although
the sample sizes of these two studies were small, a CNV analysis
involving 2195 autistic subjects indicated that CNTN4 deletions
and duplications are associated with ASDs (Betancur et al., 2009).
In a cohort of ASDs subjects, a CNV in the CNTN5 gene was iden-
tiﬁed in one individual. In addition, a CNTN6 deletion has also
been found in an autistic family (Zuko et al., 2013).
Cntn6 knockout mice exhibited slower learning in terms of
equilibrium and vestibular senses (Zuko et al., 2013), indicat-
ing that Cntn6-deﬁciency leads to defects in motor coordination.
Other characteristics of ASDs, such as social interaction and social
communication, remain to be determined in these mice. Cntn5
knockout mice exhibited decreased susceptibility to audiogenic
seizures and impaired hearing, whichmay be related to the impair-
ment of sensory information integration reminiscent of ASDs
(Zuko et al., 2013).
SYNAPTIC RECEPTORS AND AUTISM SPECTRUM DISORDERS
GABA receptors
Gamma-aminobutyric acid is the major inhibitory neurotrans-
mitter in the human brain and is synthesized from excitatory
neurotransmitter glutamate via the action of glutamate decar-
boxylase (GAD) enzymes, which have two main isoforms, GAD65
and GAD67. There are two main types of GABA receptors,
ionotropic GABAA receptors and metabotropic GABAB recep-
tors. GABAB receptors are localized at pre-, post-, or extrasynaptic
sites as functional heterodimers, whereas GABAA receptors are
the major mediators of fast inhibitory neurotransmission in the
mammalian brain.
There are three GABAA receptor genes (GABRB3, GABRA5,
and GABRG3) localized on the human chromosome 15q11–q13,
a part of the genome which is involved with genome instabil-
ity, gene expression, imprinting and recombination and is one
of the most complex regions in the genome (Martin et al., 2000).
Duplications of the 15q11–13 locus have been observed in ASDs
in several studies (Bolton et al., 2001; Kwasnicka-Crawford et al.,
2007; Depienne et al., 2009). Duplication of the region containing
GABAA receptor subunits may lead to excessive inhibitory neu-
rotransmission due to gene dosage; however, an in vitro study
using a human neuronal cell line carrying a maternal 15q duplica-
tion showed that this variant leads to reduced GABRB3 expression
via impaired homologous pairing (Meguro-Horike et al., 2011),
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suggesting that 15q11–q13 genes are regulated epigenetically at
the level of both inter- and intra-chromosomal associations and
that chromosome imbalance disrupts the epigenetic regulation of
genes in 15q11–q13.
Moreover, mouse models mimicking human 15q11–q13 dupli-
cation have exhibited features of autism, such as poor social
interaction, behavioral inﬂexibility, and abnormal ultrasonic
vocalizations (Nakatani et al., 2009).
GABAB receptors play an important role in maintaining
excitatory-inhibitory balance in brain. In autistic brain subjects,
researchers have found that the expression of GABAB receptor
subunits GABAB receptor 1 (GABBR1) and GABAB receptor 2
(GABBR2) were signiﬁcantly reduced (Fatemi et al., 2009). Fur-
thermore, clinical trials show that the selective GABAB receptor
agonist STX209 (arbaclofen) has a potential to improve social
function and behavior in patients with fragile X syndrome andwas
generally well-tolerated in ASDs individuals (Berry-Kravis et al.,
2012; Erickson et al., 2014).
In vitro, STX209 (arbaclofen, R-baclofen) can correct the
elevated basal protein synthesis in the hippocampus of Fmr1-
knockout mice, an animal model of Fragile X syndrome. In
vivo, acute administration of STX209 can decrease mRNA trans-
lation in the cortex of Fmr1-knockout mice. Furthermore, the
chronic administration of STX209 in juvenile mice can improve
the increased spine density in Fmr1-knockout mice (Henderson
et al., 2012). Since ASDs individuals have something in common
with Fragile X syndrome, this implies that GABAB receptor agonist
STX209 may also improve synaptic abnormalities in ASDs.
Consistent with the genetic evidence for the involvement of
GABAergic genes in ASDs, the expression of GABAergic genes
and related proteins have been reported to be reduced in the post-
mortem ASDs brain. GAD65 and GAD67 proteins were reduced
in the cerebellum and parietal cortex (Fatemi et al., 2002), GAD67
mRNA was reduced in cerebellar Purkinje cells (Yip et al., 2007),
and GABAA receptor binding was reduced in the hippocampus
(Blatt et al., 2001) and anterior and posterior cingulate cortices
(Oblak et al., 2009, 2011).
Although technical difﬁculties still exist, researchers have
attempted to measure GABA function in vivo, and these results
support the presence of GABAergic defects inASDs patients. Using
protonmagnetic resonance spectroscopy ([1H]MRS;Harada et al.,
2011) reported that GABA concentrations were reduced in the
frontal cortex of ASDs children, whereas no differences were
observed in the basal ganglia (Harada et al., 2011). Two studies
using SPECT (Single Photon Emission Computed Tomography)
found reductions in GABAA receptors in both ASDs adults and
children (Mori et al., 2012; Mendez et al., 2013).
In addition to the genes/proteins involved directly in GABA
synthesis and transmission, many other factors exert indirect
effects on GABA functioning through the regulation of gene
expression, receptor trafﬁcking, and downstream signaling path-
ways; therefore, GABAergic dysfunction could also be a down-
stream consequence of mutations in the genes involved in the
increase or decrease of GABA transmission. CNTNAP2, which is a
part of the NRXN family, has been associated with autism (Gregor
et al., 2011; Stein et al., 2011). CNTNAP2 knockout mice showed
speciﬁc deﬁcits in inhibitory signaling, with reduced GAD1
expression and a reduced number of GABAergic interneurons
(Peñagarikano et al., 2011). Similar ﬁndings have been observed
in another ASDs candidate gene model; CADPS2 knockout mice
showed reduced cortical parvalbumin GABA interneurons and a
reduced number of cerebellar Purkinje cells (Sadakata et al., 2007).
Glutamate receptors
Glutamate is the major excitatory neurotransmitter in the human
brain. Glutamate receptors (GluARs) are composed of ionotropic
glutamate receptors (iGluRs) and metabotropic glutamate recep-
tors (mGluRs). Findings from genetic studies, post-mortem brain
studies, animal models, and clinical drug trials have implicated a
dysfunctional glutamatergic system in ASDs; however, hypo- and
hyperfunction coexists in different forms of ASDs.
Ionotropic glutamate receptors are classiﬁed into NMDA
(N-methyl-D-aspartate), AMPA (2-amino-3-hydroxy-5-methyl-
4-isoxazolepropionic acid), and kainate receptors based on struc-
tural, pharmacological, and physiological properties. iGluRs are
tetramers encoded by 18 genes. NMDARs are obligate heteromers
formed as tetramers from the co-assembly of GluN1, GluN2A-
GluN2D, GluN3A, and GluN3B subunits. Each NMDAR channel
contains a combination of two GluN1 and two GluN2A–GluN2D
subunits or two GluN1 with one GluN2 and one GluN3 sub-
unit. AMPARs are homo- or hetero-tetramers formed from the
GluA1–GluA4 subunits and are Mg2+-insensitive. Kainate recep-
tors are tetramers formed fromcombinations of theGluK1–GluK5
subunits.
Several genetic studies have reported that NMDARs genes are
associated with ASDs. Two studies that sequenced ASDs patients
identiﬁed rare disruptive mutations in the GluN2B (GRIN2B)
gene (Tarabeux et al., 2011; O’Roak et al., 2012). Common poly-
morphisms in GRIN2B and GRIN2A have also been associated
with ASDs (Barnby et al., 2005; Yoo et al., 2012). Interestingly,
the NMDAR subunits have differential expression during devel-
opment, with GluN2B expressed early in development, followed
by GluN2A during later development and synapse maturation
(Sanz-Clemente et al., 2013).
Ramanathan et al. (2004) identiﬁed a 19 mb deletion of chro-
mosome 4q in an ASDs child, which included the AMPA 2 gene
that encodes the glutamate receptor GluR2 sub-unit (Ramanathan
et al., 2004). One study identiﬁed chromosome 6q21 as a candi-
date region for autism and found a functional SNP in glutamate
receptor 6 (GluR6 or GRIK2) gene associated with ASDs (Jamain
et al., 2002).
A post-mortem brain study also found that ASDs patients have
speciﬁc abnormalities in AMPA receptors and glutamate trans-
porters in the cerebellum (Purcell et al., 2001). The mRNA levels
of excitatory amino acid transporter 1 and glutamate receptor
AMPA1 (GluA1) were signiﬁcantly increased in autism sub-
jects, and AMPAR density was decreased in the ASDs cerebellum
(Purcell et al., 2001).
Parvalbumin-selective NMDAR 1 knockout (NR1 KO) mice
exhibited autism-like phenotypes compared with wild-type mice;
the N1 ERP latency was delayed, sociability was reduced, and
mating USVs were impaired (Saunders et al., 2013).
The administration of acute PCP and ketamine, NMDAR
antagonists, has been shown to mimic the symptoms of autism
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in humans (Carlsson, 1998). Based on this phenomenon and
neuroimaging and neuroanatomical studies, Carlsson (1998)
proposed that infantile autism is a hypoglutamatergic disorder.
Recently, both the use of an NMDAR agonist and antagonist has
been reported in ASDs patients. Daily doses of D-cycloserine, an
NMDAR glycine site partial agonist, signiﬁcantly improved social
withdrawal (Posey et al., 2004), and daily doses of amantadine
(memantine), an NMDAR non-competitive antagonist, reduced
some negative symptoms of autism, such as hyperactivity (King
et al., 2001; Chez et al., 2007).
mGluRs are members of the group C family of G-protein-
coupled receptors. mGluRs have seven transmembrane domains
that span the cell membrane. Differently to iGluRs, they are not
ion channels. There are eight different types of mGluRs, namely
mGluR1 to mGluR8, which are divided into three groups, group
1, group 2, and group 3. mGluR1 and mGluR5 belong to group 1
family, mGluR2, mGluR3, and mGluR4 belong to group 2 family,
and mGluR6, mGluR7, and mGluR8 belong to group 3 family.
They can regulate neuronal excitability, learning, and memory.
A study using high-throughput multiplex sequencing revealed
signiﬁcant enrichment of rare functional variants in the mGluR
pathway in non-syndromic autism cases. (Kelleher et al., 2012).
Most recently, in a valproate-induced rat model of autism, the
expressions of mGluR2/3 protein and mGluR2 mRNA were found
signiﬁcantly reduced. N-acetylcysteine (NAC) recued social inter-
action and anxiety-like behaviors of the VPA-exposed rats. In
addition, these effects can be blocked by intra-amygdala infu-
sion of mGluR2/3 antagonist LY341495 (Chen et al., 2014). These
results indicate that the disruption of social interaction in VPA
induced rats could be restored by NAC, which may depend on the
activation of mGluR2/3.
A decrease in mGluR has been found in PTEN knockout mice
showing autism-like behavioral deﬁcits (Lugo et al., 2014). By
reducing 50% of mGluR5 expression, several abnormalities of
Fmr1 knockout mice can be rescued. For example, density of
dendritic spines on cortical pyramidal neurons and basal pro-
tein synthesis in hippocampus are increased, inhibitory avoidance
extinction and audiogenic seizures are improved (Dolen et al.,
2007).
CONCLUDING REMARKS
In this review, we have summarized ﬁndings about some synapse
proteins and receptors linked to ASDs. Due to different sample
sizes and research methods, some results need further replication
in additional and larger samples. For some of the synapse pro-
tein defects described in this review, animal model studies are
lacking. Furthermore, genetic mutations only have been found in
some ASDs subjects. Many patients do not exhibit these types of
changes. Other signaling pathways, such as MAPK/JNK, have been
correlated with synapse pathways in the pathogenesis of ASDs.
Therefore, an intriguing question for future work is whether other
signaling pathways have crosstalk with synapse pathways during
the occurrence of ASDs.
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